• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Orthofix Medical Inc.

    11/13/24 5:03:21 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care
    Get the next $OFIX alert in real time by email
    SC 13G 1 ofix13gnov132024.txt SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 SCHEDULE 13G (Rule 13d-102) Orthofix Medical Inc. (Name of Issuer) Common Stock 68752M108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act. CUSIP NO. 68752M108 Page 2 of 4 Pages 1) Name of Reporting Person(s) I.R.S. Identification No. of Above Person (entities only) Paradigm Capital Management, Inc. 14-1770168 ----------------------------------------------------------------------------- 2) Check the Appropriate Box if a Member of a Group (a)_____ (b)_____ Not Applicable ----------------------------------------------------------------------------- 3) SEC Use Only ----------------------------------------------------------------------------- 4) Citizenship or Place of Organization New York ----------------------------------------------------------------------------- NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH (5) Sole Voting Power 2,556,500 (6) Shared Voting Power -0- (7) Sole Dispositive Power 2,556,500 (8) Shared Dispositive Power -0- ----------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned by Each Reporting Person 2,556,500 ----------------------------------------------------------------------------- 10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares Not Applicable ----------------------------------------------------------------------------- 11) Percent of Class Represented by Amount In Row (9) 6.69% ----------------------------------------------------------------------------- 12) Type of Reporting Person IA ----------------------------------------------------------------------------- CUSIP NO. 68752M108 Page 3 of 4 Pages Item 1(a) Name of Issuer: Orthofix Medical Inc. Item 1(b) Address of Issuer's Principal Executive Offices: 3451 Plano Parkway Lewisville, TX 75056 Item 2(a) Name of Person Filing: Paradigm Capital Management, Inc. Item 2(b) Address of Principal Business Office: Nine Elk Street, Albany, New York 12207 Item 2(c) Citizenship: A New York State Corporation Item 2(d) Title of Class of Securities: Common Stock Item 2(e) Cusip Number: 68752M108 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d- (b) or 9c), check whether the person filing is a: (e) [X] an investment adviser in accordance with 240.13d-1(b) (1)(ii)(E). Item 4. Ownership. (a) Amount beneficially owned: 2,556,500 (b) Percent of class: 6.69% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 2,556,500 (ii) Shared power to vote or direct the vote: -0- (iii) Sole power to dispose or to direct the disposition of: 2,556,500 (iv) Shared power to dispose or to direct the disposition of: -0- CUSIP NO. 68752M108 Page 4 of 4 Pages Item 5. Ownership of 5% or Less of a Class. If this statement is being filed to report the fact as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]. Item 6. Ownership of more than 5% on Behalf of Another Person. All securities reported in this Schedule 13G Report are owned by advisory clients of the Reporting Person. Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not Applicable Item 8 Identification and Classification of Members of the Group. Not Applicable Item 9 Notice of Dissolution of Group. Not Applicable Item 10. Certification. By signing below I (we) certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my (our) knowledge and belief, I (we) certify that the information set forth in this statement is true, complete and correct. Dated: November 13, 2024 PARADIGM CAPITAL MANAGEMENT, INC. By /s/ Gregg A. Miller Gregg A. Miller, Chief Compliance Officer Telephone: (518) 431-3500 - 4 -
    Get the next $OFIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OFIX

    DatePrice TargetRatingAnalyst
    1/27/2026$14.00Hold
    TD Cowen
    10/28/2025$22.00Buy
    Stifel
    1/22/2025$24.00Buy
    Canaccord Genuity
    11/8/2024$18.00 → $24.00Hold → Buy
    Stifel
    5/8/2024$15.00 → $20.00Neutral → Buy
    ROTH MKM
    10/20/2023$12.00Neutral
    ROTH MKM
    9/12/2023Buy → Neutral
    BTIG Research
    9/12/2023Buy → Hold
    Stifel
    More analyst ratings

    $OFIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Orthofix to Participate in Upcoming Investor Conferences

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Orthofix will participate in the following investor conferences: Goldman Sachs 47th Annual Global Healthcare Conference - Miami Beach, June 8, 2026, Fireside Chat Time: 8:40 am Eastern Time Truist Securities MedTech Conference - Boston, June 16, 2026, 1x1 Meetings Only Interested parties can access the live and archived webcast of the Goldman Sachs fireside chat in the "Events & Presentations" section of the Orthofix Investor Relations Website at ir.orthofix.com. Internet Posting of Information Orthofix regularly shares important updates in the "Investors" section of its websi

    5/18/26 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix Expands Pediatric Limb Reconstruction Portfolio with New FITBONE™ Innovation at POSNA 2026 Annual Meeting

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced new pediatric limb reconstruction innovations that expand treatment options for pediatric and small stature patients. The Company will highlight these advances at the Pediatric Orthopedic Society of North America (POSNA) 2026 Annual Meeting, which takes place May 6-8, 2026, at the Rosen Shingle Creek Hotel in Orlando, Florida. At POSNA 2026, Orthofix will showcase its comprehensive pediatric limb reconstruction portfolio at exhibit booth #34, including the recently launched FITBONE Trochanteric Intramedullary Lengthening System and new enhancements to its OrthoNext™ planning software platform

    5/6/26 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine Commercial Channel Actions; Reaffirms Full-Year 2026 Financial Guidance

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2026, reflecting steady execution following recent spine commercial channel actions. Based on first-quarter performance, the Company reaffirmed its full-year 2026 financial guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6™ product lines. Highlights First quarter 2026 reported net sales of $196.7 million, including sales from M6 artificial cervical and lumbar discs. Non-GAAP pro forma net sales of $196.4 million, excluding sales from M6 discs, incre

    5/5/26 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    SEC Filings

    View All

    SEC Form SD filed by Orthofix Medical Inc.

    SD - Orthofix Medical Inc. (0000884624) (Filer)

    5/29/26 10:13:47 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Orthofix Medical Inc. (0000884624) (Filer)

    5/21/26 8:00:44 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Orthofix Medical Inc.

    10-Q - Orthofix Medical Inc. (0000884624) (Filer)

    5/5/26 7:03:46 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Henneman John B Iii bought $61,295 worth of shares (5,000 units at $12.26), increasing direct ownership by 6% to 90,809 units (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    5/8/26 4:52:20 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Large owner Engine Capital Management, Lp bought $2,232,927 worth of shares (184,896 units at $12.08) (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    5/7/26 6:15:58 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Director Capps Vickie L bought $62,324 worth of shares (5,000 units at $12.46), increasing direct ownership by 22% to 27,585 units (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    3/10/26 4:13:55 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Orthofix with a new price target

    TD Cowen initiated coverage of Orthofix with a rating of Hold and set a new price target of $14.00

    1/27/26 8:48:16 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Stifel resumed coverage on Orthofix with a new price target

    Stifel resumed coverage of Orthofix with a rating of Buy and set a new price target of $22.00

    10/28/25 7:09:19 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Canaccord Genuity initiated coverage on Orthofix with a new price target

    Canaccord Genuity initiated coverage of Orthofix with a rating of Buy and set a new price target of $24.00

    1/22/25 7:47:50 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Juniper Investment Company, Llc

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    5/29/26 4:57:32 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    New insider Juniper Investment Company, Llc claimed ownership of 4,200,543 shares (SEC Form 3)

    3 - Orthofix Medical Inc. (0000884624) (Issuer)

    5/29/26 2:59:08 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Director Henneman John B Iii bought $61,295 worth of shares (5,000 units at $12.26), increasing direct ownership by 6% to 90,809 units (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    5/8/26 4:52:20 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Orthofix Medical Inc.

    SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)

    11/14/24 5:20:27 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Orthofix Medical Inc.

    SC 13G - Orthofix Medical Inc. (0000884624) (Subject)

    11/13/24 5:03:21 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Orthofix Medical Inc. (Amendment)

    SC 13D/A - Orthofix Medical Inc. (0000884624) (Subject)

    4/22/24 5:00:33 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Leadership Updates

    Live Leadership Updates

    View All

    Fox Factory Announces Strategic Board Refresh

    Company to Appoint Two New Independent Directors and Form Transformation Committee Focused on Operational Excellence and Margin Improvement Company Enters into Cooperation Agreement with Engine Capital DULUTH, Ga., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Fox Factory Holding Corp. (Nasdaq: FOXF) ("Fox Factory" or the "Company"), a premium brand and a global leader in the design, engineering and manufacturing of performance-defining products and systems for customers worldwide, today announced that following constructive discussions with Engine Capital ("Engine Capital") regarding opportunities to enhance operational performance and profitability, the Company will be undertaking a strategic boar

    2/9/26 4:05:00 PM ET
    $FOXF
    $OFIX
    Motor Vehicles
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Orthofix Announces Appointment of Vickie Capps to Board of Directors

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312538957/en/Vickie Capps (Photo: Business Wire) "Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix," said Michael Finegan, Chairman of Orthofix. "Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously valuable perspective as we seek to deliver profitable growth and significa

    3/12/25 8:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Financials

    Live finance-specific insights

    View All

    Orthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine Commercial Channel Actions; Reaffirms Full-Year 2026 Financial Guidance

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2026, reflecting steady execution following recent spine commercial channel actions. Based on first-quarter performance, the Company reaffirmed its full-year 2026 financial guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6™ product lines. Highlights First quarter 2026 reported net sales of $196.7 million, including sales from M6 artificial cervical and lumbar discs. Non-GAAP pro forma net sales of $196.4 million, excluding sales from M6 discs, incre

    5/5/26 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix to Report First Quarter 2026 Financial Results

    Company to Host Conference Call on Tuesday, May 5, 2026, at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7578740. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Informati

    4/21/26 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix Realigns Spine Leadership to Strengthen Focus and Execution

    Company Reports Preliminary First Quarter 2026 Net Sales and Reaffirms 2026 Outlook Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced a strategic realignment of its Spine leadership team designed to accelerate profitable growth and sharpen execution across its commercial and innovation priorities. The Company also reported preliminary, unaudited net sales results for the first quarter ended March 31, 2026. Spine Leadership Realignment To accelerate decision-making, sharpen leadership accountability, and further advance commercialization of the 7D™ navigation platform, Orthofix has streamlined its Spine organization by eliminating the rol

    4/9/26 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care